DIA Biosimilars 2013

XTL Biopharmaceuticals

XTL Biopharmaceuticals to acquire Kitov Pharmaceuticals

Thursday, June 21, 2012 12:35 PM

XTL Biopharmaceuticals, an Israel-based biopharmaceutical development company, has agreed to acquire Kitov Pharmaceuticals, an Israel-based company that researches and develops combination drug products with a focus on hypertension and pain induced by osteoarthritis.

More... »

Cenduit: Now with Patient Reminders

XTL Biopharma raises capital $3.5 million through institutional investors

Monday, March 19, 2012 11:14 AM

XTL Biopharmaceuticals, based in Herzliya, Israel, has successfully completed a private placement of securities with foreign and Israeli institutional and private investors for a total of $2.4 million, with a 6-month lock-up period.

More... »

CRF Health – eCOA Forum

XTL, Minoguard sign licensing agreement

Tuesday, March 29, 2011 11:58 AM

Israel-based XTL Biopharmaceuticals has entered into a term sheet to acquire the activity of MinoGuard, also based in Israel, by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs